Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAmortization of GoodwillAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Capital Expenditures (2016 - 2026)

Avanos Medical's Capital Expenditures history spans 13 years, with the latest figure at $6.9 million for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 193.24% to $6.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $31.6 million, a 464.29% increase, with the full-year FY2025 number at $31.6 million, up 464.29% from a year prior.
  • Capital Expenditures hit $6.9 million in Q4 2025 for Avanos Medical, down from $7.0 million in the prior quarter.
  • Over the last five years, Capital Expenditures for AVNS hit a ceiling of $11.0 million in Q2 2025 and a floor of -$10.7 million in Q4 2021.
  • Historically, Capital Expenditures has averaged $2.5 million across 5 years, with a median of $4.4 million in 2021.
  • Biggest five-year swings in Capital Expenditures: fell 29.31% in 2022 and later skyrocketed 193.24% in 2025.
  • Tracing AVNS's Capital Expenditures over 5 years: stood at -$10.7 million in 2021, then increased by 1.87% to -$10.5 million in 2022, then grew by 19.05% to -$8.5 million in 2023, then rose by 12.94% to -$7.4 million in 2024, then skyrocketed by 193.24% to $6.9 million in 2025.
  • Business Quant data shows Capital Expenditures for AVNS at $6.9 million in Q4 2025, $7.0 million in Q3 2025, and $11.0 million in Q2 2025.